Organization: BC Cancer Agency

BC genome centre becomes latest WestGrid node

The Michael Smith Genome Sciences Centre (MSGSC) has become the latest advanced research computing site for WestGrid and Compute Canada. One of eight research programs operated by the BC Cancer Agency, MSGSC is the largest capacity genomics centre of its type in Canada. It brings the number of western-based research institutions partnering with WestGrid to…

BC Genome Science Centre boosts advanced computing

BC Cancer Agency‘s Michael Smith Genome Sciences Centre is partnering with Compute Canada and WestGrid to support the expansion of its advanced research computing systems. The centre will provide researchers with access to bioinformatics software, expertise and secure computing storage as they utilize advanced computing to develop improved methods for cancer care and other disease…

Terry Fox funding supports two research projects

The Terry Fox Research Institute (TFRI) is investing $13.4 million in two established research teams focused on oncolytic viruses and leukemia. The funding flows through TFRI’s New Frontiers Program Project Grants, the Terry Fox Foundation‘s flagship program. An Ottawa-based team led by Dr John Bell, a senior scientist at the Ottawa Hospital Research Institute, will…

Compound developed by CDRD and BCCA licensed

A new oncology compound developed by the Centre for Drug Research and Development and the BC Cancer Agency has been licensed to Baltimore, MD-based Champions Oncology Inc. Irinophore is a lipid-based nanoparticle developed by using a proprietary method developed by BCCA that has demonstrated the ability to ameliorate a critical side effect of Camptosan, the…

PrioNet funds unique research collaboration

PrioNet Canada is funding a unique collaboration of academic and industry researchers to develop vaccines for prion disease that may also generate effective therapies for common cancers. Funded through PrioNet’s Bootstrap program, the research will explore certain regions within prion proteins (epitopes) that may be ideal targets for developing vaccines. The project is led by…

Aquinox completes US$14.5 million financing

Vancouver-based Aquinox Pharmaceuticals Inc has completed a US$14.5-million series ‘A’ financing to further develop targeted small molecules therapeutics based on its proprietary SH2-containing inosital phosphatase biochemical enzyme. The enzyme regulates the PI3K pathway for regulating cell growth and survival and immune cell regulation. Aquinox is a spin-off from the Univ of British Columbia and BC…

Upstream Biosciences to co-locate at BC Cancer Agency

Upstream Biosciences Inc has entered into a lease agreement with the BC Cancer Agency with the aim of collaborating with resident scientists for the development of diagnostic tests for early detection of cancer. Upstream will establish a research unit at the Echclon Innovation Centre, which also houses the BC Cancer Agencys Genome Sciences Centre. The…

FPTT signs on as Flintbox channel partner

Federal Partners in Technology Transfer (FPTT) has signed on as a channel partner to Flintbox, a national network for licensing and reporting on early-stage research. Launched in 2003 as a spin-off from the Univ of British Columbia (UBC), the online application has focused primarily on universities, providing training and learning materials for institutions that sign…

Pagtakhan attends G-8 science ministers meeting

Canada profiled its efforts to prevent the spread of infectious diseases at the 25th Carnegie Meeting of G-8 science ministers held June 12-13 in Germany. The presentation was made by secretary of state for science, research and development Dr Rey Pagtakhan. He outlined Canada’s recent experience with SARS and Mad Cow disease and the sequencing…